Impact of Preoperative Angiotensin-Converting Enzyme Inhibitor Use on Clinical Outcomes After Cardiac Surgery Maral Ouzounian, MD, Karen J. Buth, MS, Liliya Valeeva, MD, Craig C. Morton, MS, Ansar Hassan, MD, PhD, Imtiaz S. Ali, MD The Annals of Thoracic Surgery Volume 93, Issue 2, Pages 559-564 (February 2012) DOI: 10.1016/j.athoracsur.2011.10.058 Copyright © 2012 The Society of Thoracic Surgeons Terms and Conditions
Fig 1 Risk-adjusted effect of preoperative angiotensin-converting enzyme inhibitor (ACEi) use on in-hospital and long-term outcomes after coronary artery bypass grafting. (ACS = acute coronary syndrome; CI = confidence interval; HF = heart failure; ICU = intensive care unit.) The Annals of Thoracic Surgery 2012 93, 559-564DOI: (10.1016/j.athoracsur.2011.10.058) Copyright © 2012 The Society of Thoracic Surgeons Terms and Conditions
Fig 2 Risk adjusted freedom from mortality with and without preoperative angiotensin-converting enzyme inhibitor (ACEi) therapy. The Annals of Thoracic Surgery 2012 93, 559-564DOI: (10.1016/j.athoracsur.2011.10.058) Copyright © 2012 The Society of Thoracic Surgeons Terms and Conditions